News
-
-
COMMUNIQUÉ DE PRESSE
Capital B annonce la nomination de Tracy Hoyos Lopez et de Daniel Batten en tant que Conseillers Stratégiques du Conseil d'Administration pour l'expansion internationale et institutionnelle de sa stratégie de Bitcoin Treasury Company
Capital B nomme Tracy Hoyos Lopez Conseillère Stratégique pour les États-Unis et le Moyen-Orient, et Daniel Batten Conseiller Stratégique ESG. Incorporation de Capital B Treasury Limited à Abou Dhabi. Alexandre Laizet nommé CEO -
COMMUNIQUÉ DE PRESSE
UCB presents positive results from GEMZ phase 3 study at AES showing fenfluramine significantly reduces countable motor seizure frequency in CDKL5 Deficiency Disorder
UCB presents positive results from GEMZ phase 3 study at AES showing significant reduction in countable motor seizure frequency in CDKL5 Deficiency Disorder. Study demonstrates efficacy and safety of fenfluramine as adjunctive treatment -
COMMUNIQUÉ DE PRESSE
Eight years of research and development – proprietary algorithms enable the strategic scaling of trading capacities
Alphawave GmbH concludes an 8-year R&D phase, introducing scalable trading capacities. Proprietary algorithms drive strategic trading. Impressive internal trading results shared -
-
COMMUNIQUÉ DE PRESSE
Xlife Sciences AG Announces Exit of 12 Project Companies to Grupo Landsteiner and the Creation of a Scalable Transcontinental Life Sciences Platform
Xlife Sciences AG announces strategic exit of 12 projects to Grupo Landsteiner, forming a transcontinental life sciences platform with a NASDAQ listing in 2026 -
-
-
-
COMMUNIQUÉ DE PRESSE
Newron announces the US initiation of its ENIGMA-TRS 2 Phase III global clinical study with evenamide as an add-on therapy for patients with treatment-resistant schizophrenia (TRS)
Newron Pharmaceuticals initiates ENIGMA-TRS 2 Phase III global clinical study in US for treatment-resistant schizophrenia with evenamide as add-on therapy. Expecting results by Q4 2026
